| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mM * 1 mL in DMSO |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
白藜芦醇（反式白藜芦醇；SRT501）是在多种植物来源中发现的众多多酚化学物质之一。在绝大多数情况下，白藜芦醇在微摩尔范围内表现出抑制/激活作用，这在药理学上可能是可行的，尽管纳摩尔范围内的目标也已被描述[1]。 MCF-7 细胞接种于补充有 5% FBS 和增加剂量的白藜芦醇的 DME-F12 培养基中。对照细胞仅用相同体积的载体（0.1%乙醇）处理。白藜芦醇以剂量依赖性方式抑制 MCF-7 细胞的发育。添加 10 μM 白藜芦醇 6 天后，MCF-7 细胞生长受到 82% 的抑制，但添加 1 μM 时，仅抑制 10%。用 10 μM 白藜芦醇处理的细胞的倍增时间为 60 小时，而对照细胞每 30 小时倍增一次。台盼蓝排除试验表明，在 10 μM 或更低的浓度下，白藜芦醇不会损害细胞活力（90% 的活细胞），但在 100 μM 的剂量下，白藜芦醇给药 6 天后，只有 50% 的细胞存活。此外，根据 ApoAlert 膜联蛋白 V 细胞凋亡试剂盒的评估，MCF-7 细胞与 10 μM 剂量的白藜芦醇一起孵育后并未发生细胞凋亡 [2]。白藜芦醇通过上调内皮一氧化氮合酶 (eNOS) 的表达、增强 eNOS 酶活性并阻断 eNOS 解偶联来促进内皮细胞中一氧化氮 (NO) 的产生 [7]。
|
||
|---|---|---|---|
| 体内研究 (In Vivo) |
用50 mg/kg (195.5±124.8 mm3；P<0.05)或100 mg/kg白藜芦醇(反式白藜芦醇；SRT501)治疗可减少平均肿瘤体积(81.7±70.5 mm3；P<0.001)。肿瘤质量和体积有很强的相关性[3]。
|
||
| 动物实验 |
|
||
| 参考文献 |
Nat Rev Drug Discov.2006 Jun;5(6):493-506.
|
| 分子式 |
C14H12O3
|
|---|---|
| 分子量 |
228.24
|
| CAS号 |
501-36-0
|
| 相关CAS号 |
Resveratrol;501-36-0
|
| SMILES |
OC1=CC(/C=C/C2=CC=C(O)C=C2)=CC(O)=C1
|
| 化学名 |
(E)-5-(4-hydroxystyryl)benzene-1,3-diol
|
| 别名 |
SRT-501; RM-1812; SRT 501; RM 1812; SRT501; RM1812; trans-Resveratrol; CA1201; CA-1201; CA 1201; Resvida; Vineatrol 20M.
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外) |
|
|||
|---|---|---|---|---|
| 溶解度 (体内) |
Solubility in Formulation 1: 5 mg/mL (21.91 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (21.91 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (21.91 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 8: ≥ 2.5 mg/mL (10.95 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 9: 2% DMSO+30% PEG 300+ddH2O: 5mg/mL Solubility in Formulation 10: 12.5 mg/mL (54.77 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 11: 16.67 mg/mL (73.04 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3814 mL | 21.9068 mL | 43.8135 mL | |
| 5 mM | 0.8763 mL | 4.3814 mL | 8.7627 mL | |
| 10 mM | 0.4381 mL | 2.1907 mL | 4.3814 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06020313 | Recruiting | Dietary Supplement: Resveratrol Experimental |
Polyphenols Cardiovascular Diseases |
Taisy Cinthia Ferro Cavalcante | August 2023 | Not Applicable |
| NCT05874882 | Recruiting | Other: resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients |
Periodontitis | University of Baghdad | December 12, 2022 | Early Phase 1 |
| NCT06250283 | Recruiting | Dietary Supplement: Resveratrol Dietary Supplement: Placebo |
Low Bone Mass | University of Delaware | February 2, 2024 | Not Applicable |
| NCT03933163 | Active, not recruiting | Drug: Resveratrol | Friedreich Ataxia | Murdoch Childrens Research Institute | May 23, 2019 | Phase 2 |
SIRT1 activator 1
SIRT5 inhibitor 8
SIRT5 inhibitor 9
CypE-IN-1
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
COA
粤公网安备 44011102003439号